BiotechTube
Multispan, Inc.

Multispan, Inc.

Hayward, United States· Est.
multispaninc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17M

Overview

Multispan, Inc. is a long-established, privately-held contract research organization (CRO) and reagent provider specializing in GPCR and cellular drug discovery. Its core value proposition is the MULTISCREEN™ integrated platform, which consolidates proprietary cell engineering, assay development, and high-throughput screening services under one roof to improve efficiency and success rates for pharmaceutical and biotech clients. With a portfolio of over 600 stable cell lines and 2000+ assay tools, the company is positioned as a trusted, expert partner for accelerating early-stage drug discovery, particularly for challenging target classes like GPCRs.

AntibodiesDrug Discovery

Technology Platform

MULTISCREEN™ integrated platform combining proprietary cell engineering (600+ clonal stable cell lines), assay development, and high-throughput screening services for GPCRs and other membrane protein targets.

Funding History

2
Total raised:$17M
Series A$15M
Seed$2M

Opportunities

Growth is driven by the sustained high demand for GPCR-targeted drug discovery and the biopharma industry's trend towards outsourcing specialized R&D functions.
Expanding its assay portfolio 'beyond GPCRs' to other target classes (ion channels, transporters) and developing more standardized assay kits present additional avenues for market expansion.

Risk Factors

Revenue is vulnerable to downturns in biopharma R&D spending.
The company operates in a highly competitive CRO market against larger, well-capitalized players and must continuously innovate to maintain its technological edge.
Operational reputation is critical; any significant service failure could damage client trust.

Competitive Landscape

Multispan competes in the niche segment of specialized GPCR and cell-based assay services. Key competitors include large, full-service CROs (e.g., Charles River Laboratories, Eurofins Discovery) that offer similar services, as well as smaller boutique firms like DiscoverX (now part of Eurofins) and Reaction Biology. Its differentiation lies in its integrated, single-site model, extensive proprietary cell line library, and emphasis on rapid turnaround for lead optimization.

More companies in Small Molecule Drugs →More companies in United States →